Published online Oct 26, 2019. doi: 10.12998/wjcc.v7.i20.3282
Peer-review started: May 21, 2019
First decision: July 30, 2019
Revised: August 30, 2019
Accepted: September 9, 2019
Article in press: September 9, 2019
Published online: October 26, 2019
Systemic amyloidosis in which multiple systems can be involved has become a common clinical disease. When the liver is affected, symptoms such as abdominal distension, fatigue, edema, liver, and jaundice could appear. To date, hepatic amyloidosis combined with hepatic venular occlusive disease and Budd-Chiari syndrome has not been reported.
A 54-year-old female patient was admitted to the Beijing Shijitan Hospital with hepatic amyloidosis leading to hepatic venular occlusion and Budd-Chiari syndrome in 2018. The patient underwent surgery 1 mo previously for liver rupture and hemorrhage after Budd-Chiari syndrome was diagnosed. She was diagnosed with hepatic venular occlusion, liver amyloidosis, and Budd-Chiari syndrome (i.e. extensive hepatic vein occlusion). Transjugular intrahepatic portosystem shunt was performed. After the treatment, the clinical symptoms improved markedly with increase in urine volume.
Hepatic amyloidosis with hepatic venous occlusion and Budd-Chiari syndrome is relatively rare clinically, and transjugular intrahepatic portosystem shunt is an effective treatment for this disease.
Core tip: Transjugular intrahepatic portosystem shunt is an effective treatment for hepatic amyloidosis with hepatic venous occlusion and Budd-Chiari syndrome.